A5068850691- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Liver Disease and Transplantation
- Pediatric Hepatobiliary Diseases and Treatments
- Organ Transplantation Techniques and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Drug Transport and Resistance Mechanisms
- Celiac Disease Research and Management
- Inflammatory Bowel Disease
- Dermatology and Skin Diseases
- Liver physiology and pathology
- Diabetes and associated disorders
- Pancreatitis Pathology and Treatment
- Systemic Sclerosis and Related Diseases
- Gastrointestinal disorders and treatments
- Urticaria and Related Conditions
- Cancer, Lipids, and Metabolism
- Hepatitis Viruses Studies and Epidemiology
- Gastrointestinal Bleeding Diagnosis and Treatment
- Renal function and acid-base balance
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal Transplantation Outcomes and Treatments
Beth Israel Deaconess Medical Center
2016-2025
Harvard University
2016-2025
RELX Group (Netherlands)
2022
University Gastroenterology
2022
University of Michigan
2017-2018
Hadassah Medical Center
2015-2016
Tufts Medical Center
2010-2014
Tufts University
2013
Universidad Nacional Autónoma de México
2009
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2005
Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated better long-term outcome. However, second-line therapies currently recommended only when ALP remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, considered good responders to UDCA, were significant survival gains. Approach Results: performed a retrospective cohort study 1047 PBC who...
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of ursodeoxycholic acid. Up to 40% patients do not, however, respond adequately acid and therefore still remain at risk disease progression cirrhosis. introduction obeticholic as second-line therapy for failing has improved outcomes PBC. There remains, need better treatment higher risk. greatest threat facing our efforts improve in PBC is,...
Guidelines recommend routine screening of liver function tests (LFTs) in patients diagnosed with celiac disease (CD). However, little is known about the prevalence disorders CD outside Europe. Our aims were to estimate LFT abnormalities and evaluate effect a gluten-free diet (GFD) on LFTs.Adult biopsy-proven identified from prospectively maintained database matched healthy controls. levels for women men defined as abnormal based Third National Health Nutrition Examination Survey (NHANES III)...
The presence of cirrhosis poses an increased risk both thrombosis and bleeding in individuals with chronic liver disease. This duality is a result dynamic disequilibrium between procoagulant anticoagulant states cirrhosis. mechanism this imbalance remains unclear. It known that the progression leads to decreased synthetic function concurrent lack natural anticoagulants. Other proposed mechanisms contributing hemostatic include platelet production, destruction from hypersplenism, synthesis...
Abstract Background and Aim The prevalence clinical significance of extrahepatic autoimmune diseases (EHAIDs) have not been evaluated in a large cohort primary biliary cholangitis (PBC). Methods medical records 1554 patients with PBC from 20 international centers were retrospectively reviewed. Development decompensated cirrhosis (ascites, variceal bleeding, and/or hepatic encephalopathy) hepatocellular carcinoma considered endpoints. Results A total 35 different EHAIDs diagnosed 440 (28.3%)...
Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic and cirrhosis. Ursodeoxycholic acid obeticholic are the only 2 Food Drug Administration (FDA)-approved medications for primary cholangitis. Unfortunately, up 40% patients with have incomplete response ursodeoxycholic acid, warranting essential need additional therapeutics. Peroxisome proliferator-activated receptor agonists...
INTRODUCTION: Risk stratification based on biochemical variables is a useful tool for monitoring ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC). Several UDCA response criteria and scoring systems have been proposed risk prediction in PBC, but these not validated large external cohorts. METHODS: We performed study data of 1746 UDCA-treated PBC from 25 centers Europe, United States, Canada. The prognostic performance the (GLOBE UK-PBC) (Barcelona, Paris I,...
Primary sclerosing cholangitis (PSC) is the leading indication of liver transplantation (LT) among autoimmune disease patients. There a scarcity studies comparing survival outcomes between living-donor transplants (LDLT)s and deceased-donor (DDLTs) in this population. Using United Network for Organ Sharing database, we compared 4679 DDLTs 805 LDLTs. Our outcome interest was post-LT patient graft survival. A stepwise multivariate analysis performed, adjusting recipient age, gender, diabetes...
Background Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment. The changing landscape of hepatocellular carcinoma (HCC) in liver transplant (LT) recipients lacks a thorough description the outcomes HCC based on etiology. Objective To assess waitlist (WL) dropout and graft survival LT candidates etiology post-DAA era. Methods This retrospective cohort study analyzed United Network Organ Sharing/Organ Procurement Transplant data from 2015 to 2022. Graft was...
Aim: To evaluate the clinical characteristics and healthcare resource utilization for acute care its costs patients with primary biliary cholangitis (PBC) or without cirrhosis. Materials & methods: This retrospective observational cohort study was conducted using two datasets (Komodo's Healthcare Map™ [Komodo Health] Optum Clinformatics® Data Mart [CDM] database) between 2015 2023. Patients (≥18 years) PBC were identified based on ≥1 inpatient ≥2 outpatient claims. (hospitalizations...